Trials is an open access, peer-reviewed, online journal that encompasses all aspects of the performance and findings of randomized controlled trials in health. We publish articles on general trial methodology as well as protocols, commentaries and traditional results papers - regardless of outcome or significance of findings.
- Doug Altman, University of Oxford
- Curt Furberg, Wake Forest University of Medicine
- Jeremy Grimshaw, Ottawa Health Research Institute
Preclinical studies suggest baclofen could be used in treating persistent hiccups in stroke patients. Here, the results of this randomised controlled trial provide evidential support for this, though the authors highlight the need for larger studies.
Sample size requirements to estimate key design parameters from external pilot randomised controlled trials
Little consensus exists on how large a pilot study needs to be to aid the design of definite RCTs. This simulation study investigated the effect of sample size on precision and power under three realist scenarios, resulting in recommendations for external pilot study sizes for continuous outcomes and rare events.
Community-acquired pneumonia is one of the leading infectious causes of death worldwide. The use of systemic corticosteroids in addition to standard treatment is controversial; therefore, this trial will investigate the effect of adjunct glucorticosteroids in 800 patients with community acquired-pneumonia requiring hospitalization, in particular, differences in time to clinical stability.
The COMET Initiative aims to facilitate the development of an agreed minimum set of outcomes that should be measured and reported in all clinical trials. Here, a Delphi study is described, aimed to achieve consensus on how to select outcome measurement instruments for these core outcomes.
Missing outcome data in RCTs can result in misleading conclusions. Therefore, this review investigated the reporting of missing data and methods used to address problems caused by missing data in one hundred recent trial publications. Unfortunately, the authors found large inconsistencies in both reporting and addressing missing data.
Latest from the ISRCTN Register
- 23 July 2014
- ISRCTN14526380 - The PASSAGE Program: A structured multicomponent interdisciplinary group intervention for the self-management of fibromyalgia.
- 23 July 2014
- ISRCTN05107772 - Quicksilver: a study to assess the safety of a new MRI approach to pre-operatively stage rectal cancer and guide treatment
- 23 July 2014
- ISRCTN31552904 - Determination of Corneal Biomechanical Properties in-vivo using a Contact Device
Trials supports the AllTrials initiative, campaigning for the registration of all trials past and present, and the reporting of full methods and the results of all trials.
Restoring invisible and abandoned trials: a call for people to publish the findings published in the BMJ in June 2013, calling for wider publication of stopped and unfinished trials.
Professor Doug Altman graduated in statistics from the University of Bath and has worked for the Medical Research Council as a statistical consultant in a wide variety of medical areas. In 1988 he became head of the newly formed Medical Statistics Laboratory (now Medical Statistics Group) at ICRF (now Cancer Research UK), and in 1995 also became founding director of the Centre for Statistics in Medicine (CSM) in Oxford. In 1997, Professor Altman received the Bradford Hill Medal for his contributions to medical statistics and a DSc from the University of London and, in 1998 was made Professor of Statistics in Medicine by the University of Oxford. His varied research interests include the use and abuse of statistics in medical research, studies of prognosis, regression modelling, systematic reviews and meta-analysis, randomised trials, and studies of medical measurement.
Curt D. Furberg
Professor Curt D. Furberg is a co-Editor-in-Chief of Trials. He is a Professor of Public Health at Wake Forest University Health Sciences, where he has been since 1986. Professor Furberg earned his MD in Sweden in 1963 and has worked at the Minneapolis LRC Clinic as the Chief of the Clinical Trials Branch and the Clinical Trials Research Branch of the National Heart, Lung, and Blood Institute - where he was the Associate Director for the Clinical Applications and Prevention Program. In addition, Professor Furberg is a nationally and internationally recognized expert on the design, conduct, analysis and monitoring of clinical trials. He has worked closely with investigators at the NIH and several pharmaceutical companies and is also a world-renowned cardiovascular epidemiologist with special expertise in lipid-lowering and blood pressure-lowering therapies. He is a strong proponent for evidence-based medicine, and his public health background provides a strong foundation for his views on drug evaluation and patient safety.
Professor Jeremy Grimshaw is the Director of the Clinical Epidemiology Program at the Ottawa Health Research Institute and the Director of the Center for Best Practice at the University of Ottawa. He holds a Tier 1 Canadian Research Chair in health knowledge transfer and uptake and was made a Professor of Medicine by the University of Ottawa. Prior to this, he held a Personal Chair in health services research at the University of Aberdeen and was the Program Director of the Effective Professional Program within health services research, one of the largest implementation research programs within the UK. Professor Grimshaw’s research interests are in knowledge translation,quality improvement,complex interventions. systematic reviews, cluster randomized trials, quasi experimental studies and behavioural theories (and their application to professional behaviour).